Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.

doi:10.1007/s00432-022-03984-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.

Journal of cancer research and clinical oncology - 1 Feb 2023

Gursoy Pınar, Tatli Ali Murat, Erdem Dilek, Goker Erdem, Celik Emir, Demirci Nebi Serkan, Sakin Abdullah, Atci Muhammed Mustafa, Bayram Ertuğrul, Telli Tuğba Akın, Bilgin Burak, Bilici Ahmet, Akangunduz Baran, Balli Sevinç, Demirkazik Ahmet, Selçukbiricik Fatih, Menekse Serkan, Cavdar Eyyüp, Ozturk Akın, Bekmez Esma Türkmen, Turhal Serdal, Kilickap Sadettin, Yildirim Hasan Çağrı, Oyan Başak, Aksoy Asude, Turkoz Fatma Paksoy, Kut Engin, Katgi Nuran, Sakalar Teoman, Akyol Murat, Ellez Halil İbrahim, Topcu Atakan, Erdoğan Atike Pınar, Pilanci Kezban Nur, Hedem Engin, Arak Hacı, Akdeniz Nadiye, Alan Özkan, Yapar Burcu, Nart Deniz, Yumuk Perran Fulden

Abstract excerpt

OBJECTIVES: To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib as first line treatment between 2012 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Afatinib

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Open in PubMed

Identifiers

PMID: 35381885
DOI: 10.1007/s00432-022-03984-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.PMID 35381885Read ↗

Real Life Comparison of Afatinib and Erlotinib in Non-small Cell Lung Cancer With Rare EGFR Exon 18 and Exon 20 Mutations: a Turkish Oncology Group (TOG) Study.Semantic proximity Read ↗

Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study.Semantic proximity Read ↗

Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.Semantic proximity Read ↗

Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study.Semantic proximity Read ↗

Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations.Semantic proximity Read ↗

The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic AlterationsSemantic proximity Read ↗

Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709X.Semantic proximity Read ↗

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring <em>EGFR</em> exon 20 mutationsSemantic proximity Read ↗

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief ReportSemantic proximity Read ↗

From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatmentSemantic proximity Read ↗

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.